Marijuana 1-to-3 Act of 2025
- Bill Number
- H.R. 4963
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Crime and Law Enforcement
- Status
- Introduced
- Latest Action
- 2025-08-12: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2025-11-21T12:04:05Z
AI-Generated Summary
Purpose of the Legislation
The Marijuana 1-to-3 Act of 2025 aims to reclassify marijuana (also spelled "marihuana" in the law) under federal drug scheduling rules, moving it from a highly restricted category to one that recognizes some medical uses and lower risk of abuse.
Key Provisions
- Short Title: The bill is named the "Marijuana 1-to-3 Act of 2025."
- Rescheduling Directive: The Attorney General must issue an order within 60 days of the bill's enactment to transfer marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA).
- Schedule I drugs (under current law) are seen as having high potential for abuse and no accepted medical use in the U.S., making them illegal to possess, use, or distribute without special permission.
- Schedule III drugs have a moderate to low potential for abuse and an accepted medical use, allowing for prescriptions and regulated distribution.
- This action overrides the standard CSA processes for scheduling changes (sections 201 and 202), which normally involve public hearings, scientific reviews, and rulemaking by the Department of Justice and Drug Enforcement Administration (DEA).
Significant Changes to Existing Law
- Bypassing Normal Procedures: The bill eliminates the usual multi-step review for rescheduling, directly mandating the change without needing input from advisory committees or additional evidence gathering.
- Definition Alignment: Uses the CSA's existing definition of "marihuana," which includes all parts of the cannabis plant and its derivatives, but excludes certain non-psychoactive parts like hemp seeds or fiber (as defined in other federal laws).
- No other amendments to the CSA are made; this is a targeted shift in scheduling only.
Potential Impacts
- On Government Agencies: The DEA and Department of Justice would need to update enforcement priorities, regulations, and guidelines quickly (within 60 days), potentially reducing federal prosecutions for medical marijuana activities. Research approvals by agencies like the National Institutes of Health could become easier.
- On Citizens: Individuals with medical needs might gain better access to marijuana-based treatments through prescriptions, as Schedule III status allows for FDA-approved drugs. However, recreational use remains illegal federally, and possession could still lead to penalties in states without legalization.
- On International Relations: As a signatory to U.N. treaties classifying cannabis as a highly dangerous substance, this rescheduling could prompt U.S. diplomatic discussions or treaty reinterpretations, but it is unlikely to cause major conflicts since the change focuses on domestic medical recognition.
- Broader effects include potential increases in clinical research and state-federal alignment in legalized states, though federal banking and tax restrictions on cannabis businesses (under laws like the IRS's Section 280E) would persist.
Main Stakeholders Affected
- Medical Patients and Healthcare Providers: Easier access to prescribed marijuana products for conditions like chronic pain or epilepsy.
- Researchers and Pharmaceutical Companies: Simplified processes for studying and developing cannabis-derived medicines.
- Law Enforcement and Justice System: Reduced federal resources spent on marijuana enforcement, shifting focus to higher-risk drugs; state police might see less conflict with federal law.
- States and Local Governments: Particularly those with medical or recreational marijuana programs (over 30 states as of 2025), benefiting from decreased federal interference.
- Cannabis Industry Businesses: Potential for more legitimate operations, though full federal legalization is not addressed.
- General Public: Indirect benefits through possible tax revenue increases in legal states and reduced criminal justice involvement for minor possession.
Notable Legal, Constitutional, or Political Implications
- Legal: This rescheduling could lead to court challenges from anti-drug groups arguing it undermines the CSA's scientific basis, or from advocates pushing for even broader reforms. It aligns with ongoing administrative efforts (e.g., FDA reviews) but enforces change legislatively, potentially setting precedent for future drug policy shifts without executive rulemaking.
- Constitutional: No direct constitutional issues, as Congress has authority over federal drug laws under its commerce powers; however, it may highlight tensions between federal and state laws under the 10th Amendment, especially in states asserting sovereignty over marijuana.
- Political: Represents a bipartisan step toward drug policy modernization, introduced by Rep. Steube (R-FL) and referred to key committees (Energy and Commerce, Judiciary). If passed, it could influence 2026 elections by appealing to reform advocates, but faces opposition from those concerned about increased youth access or abuse potential. The bill's brevity suggests it's a focused proposal amid broader cannabis debates, without addressing issues like expungement of records or full descheduling.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Steube, W. Gregory [R-FL-17]
Cosponsors (3)
Rep. Joyce, David P. [R-OH-14], Rep. Carter, Troy A. [D-LA-2], Rep. Mast, Brian J. [R-FL-21]
Recent Actions
- 2025-08-12: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-08-12: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-08-12: Introduced in House
- 2025-08-12: Introduced in House
Bill Versions
- Marijuana 1-to-3 Act of 2025 — issued 2025-08-12 — PDF (2 pages)